Program
ligufalimab
Also written as “AK117”, “Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine” and “AK117 in combination with AK112”.
Its studies are mostly in Neoplasms · Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Triple Negative Breast Neoplasms · Pancreatic Neoplasms, led by Akeso.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akeso | 118 open or running | phase 3since Aug 29, 2024 | Apr 14, 2020 | Dec 30, 2026phase 2 · NCT05227664 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2020First study: phase 1 study in NeoplasmsFirst studyNCT04349969 · 38 enrolled · Australia
- Jan 24, 2021Phase 1 study in NeoplasmsNCT04728334 · 49 enrolled · China
- May 19, 2021Phase 2 study in Myelodysplastic SyndromesNCT04900350 · 136 enrolled · China
- Jul 21, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT04980885 · 68 enrolled · China
- Jan 14, 20222 phase 2 studiesNCT05214482, NCT05227664
- Jul 17, 2023Phase 2 study in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaNCT05960955 · 90 planned · China
- Dec 24, 2023Phase 2 study in Higher-risk Myelodysplastic SyndromesNCT06196203 · 90 planned · United States, China
- Apr 24, 2024Phase 2 study in Leukemia, Myeloid, AcuteNCT06387420 · 180 planned · China
- Aug 29, 2024Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06601335 · 510 planned · China
- Apr 24, 2025Phase 3 study in Pancreatic NeoplasmsNCT06953999 · 999 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsNCT05227664
- Jan 2027Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06601335
- May 14, 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT06953999
TargetBeta
“A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, ”NCIt, by rule
Other programs on CD47
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| evorpaceptrule | alx-oncology-inc | phase 3 | 9 |
| Anti-PD-1/CD47 Fusion Protein HX009rule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 5 |
| CD47 Antagonist AUR103 Calciumrule | Dr. Reddy's Laboratories | phase 2 | 2 |
| 1200mg of tqb2928 injection | Sino Biopharmaceutical | phase 1 | 2 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06953999Pancreatic Neoplasms · China | 3 | Recruiting | May 14, 2027 | 999 |
| NCT06601335Squamous Cell Carcinoma of Head and Neck · China | 3 | Recruiting | Jan 2027 | 510 |
| NCT06387420Leukemia, Myeloid, Acute · China | 2 | Not yet recruiting | Apr 2026 | 180 |
| NCT06196203Higher-risk Myelodysplastic Syndromes · United States, China | 2 | Recruiting | Jan 2026 | 90 |
| NCT05960955Resectable Gastric or Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Nov 30, 2024 | 90 |
| NCT05227664Triple Negative Breast Neoplasms · China | 2 | Active, not recruiting | Dec 30, 2026 | 120 |
| NCT05214482Advanced Malignant Tumors · China | 2 | Completed | Nov 20, 2025 | 154 |
| NCT04980885Leukemia, Myeloid, Acute · China | 2 | Active, not recruiting | Sep 2025 | 68 |
| NCT04900350Myelodysplastic Syndromes · China | 2 | Active, not recruiting | Sep 2025 | 136 |
| NCT04728334Neoplasms · China | 1 | Completed | Jan 25, 2022 | 49 |
| NCT04349969Neoplasms · Australia | 1 | Completed | Nov 8, 2022 | 38 |
How it is read
Names in the registry
- “AK117”, 9 entries
- “Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine”, 1 entry
- “AK117 in combination with AK112”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 2 studies
- Myelodysplastic Syndromes, 2 studies
- Leukemia, Myeloid, Acute, 2 studies
- Triple Negative Breast Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.